UNICREDIT BANK/PUT/AMGEN/300/0.1/14.01.26 | Real-time BOERSE MUENCHEN 14:41:03 26/06/2024 BST | ||
| 2.65 EUR | +2.71% |
|
| Current month | -17.31% | ||
| 1 month | -16.23% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 26/06/24 | 2.65 | +2.71% |
| 25/06/24 | 2.58 | -1.90% |
| 24/06/24 | 2.63 | -7.39% |
| 21/06/24 | 2.84 | -2.74% |
| 20/06/24 | 2.92 | -2.99% |
Real-time BOERSE MUENCHEN
Last update June 26, 2024 at 02:41 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | AMGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HD28NF |
| ISIN | DE000HD28NF7 |
| Date issued | 29/01/2024 |
| Strike | 300 $ |
| Maturity | 14/01/2026 (567 Days) |
| Parity | 10 : 1 |
| Emission price | 3.08 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.2 € |
|---|---|
| Lowest since issue | 2.48 € |
| Spread | 0.02 € |
| Spread % | 0.74% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
319.3
USD
Average target price
316.4
USD
Spread / Average Target
-0.90%
- Stock Market
- Warrants
- Warrant
